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Firms’ reshaping of commercialization practices to overcome the  
‘not invented here’ phenomenon in public healthcare organizations 
 
Helle Aarøe Nissen, Majbritt Rostgaard Evald and Ann Højbjerg Clarke 
 
 
ABSTRACT 
 
The present study is rooted in Public Private Innovation (PPI) projects where public 
hospitals and private firms engage in cross-sector collaboration with a view to developing new 
welfare solutions targeting public sector needs. Research into PPI is mainly focused on public 
management of innovation processes. Consequently, PPI is rarely examined from a private sector 
perspective, including how private firms seek to commercialize new innovations after co-
creating these innovations in collaboration with public organizations. However, 
commercialization is a critical aspect of innovation because it embraces the learning process 
whereby newly developed innovations are put into use in society so that they may create value 
for citizens as well as public servants while generating value in private firms. This article 
contributes to the literature on collaborative innovation in the public sector by elucidating how 
private firms commercialize co-created welfare solutions. The empirical setting is a multiple case 
study consisting of four PPI projects conducted in public Danish healthcare. The findings reveal 
that PPI firms experience the ‘not invented here’ (NIH) phenomenon across Danish hospitals. 
This phenomenon appears in the short run to hamper the firms’ commercialization of new 
welfare innovations. However, in the longer run, firms respond to NIH by reshaping their 
commercialization practices as they redirect their focus towards the potential benefits of 
exporting their new welfare solutions to international healthcare systems.   
 
Key words: Commercialization, public-private innovation, not invented here, collaborative 
innovation. 
 
 
Introduction 
 
Public innovation is becoming a central topic on the political agenda in many Western 
countries. Innovation in the public sector often focuses on improvement of public services with a 
view to better meeting the needs of the citizens who demand better and more individualized 
public solutions (Sørensen and Torfing, 2012). Increasingly, public innovation is embedded in 
collaborative innovation projects that involve both public and private sector actors (Ansell and 
Torfing, 2014), also coined Public Private Innovation (hereafter PPI). Specifically, PPI refers to 
public and private actors collaborating as development partners throughout an innovation process 
to develop new solutions targeting public sector needs (Nissen et al., 2014; Weihe et al., 2011). 
Thus, PPI is based on collaborative innovation in which public and private actors jointly 
accommodate the development of new ideas and products in ways that strengthen public 
services. The institutionalization of PPI is observable particularly in the growing establishment 
of publicly funded PPI projects within Danish public healthcare (Brogaard and Petersen, 2014), 
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and in the establishment of ministerial and regional healthcare innovation units. Equally, there 
has been an increased political focus on the use of PPI projects as an approach to developing new 
welfare solutions needed to meet future demographic challenges associated with an increasingly 
aging population (Klitkou, 2011).  
 
Enhancing public innovation through the use of collaborative cross-sector innovation in 
the form of PPI projects has also gained increasing attention in academic research across 
different research fields (Evald et al., 2014). In particular, the focus has been on policy networks 
(Sørensen and Torfing, 2011; Kickert et al., 1997; Rhodes, 1997) and inter-organizational 
relationships aiming to enhance public innovation through collaboration between public and 
private actors (Nissen et al., 2014; Ansell and Torfing, 2014; Le Ber and Branzei, 2010; Pol and 
Ville, 2009; Edelenbos and Klijn, 2007). Thus, extant research into PPI primarily focuses on how 
public managers manage innovation processes at the stage where a new innovation is being 
developed through collaboration between public and private actors. PPI has rarely been 
examined from a private sector perspective, including how private firms seek to commercialize 
new welfare solutions to generate public innovation (Evald, 2014). As such, what is most 
frequently examined in current PPI literature is the phase or aspect of the innovation process in 
which a new solution is being developed. However, innovation processes do not merely include 
the creation of a new invention, but also its commercialization, i.e. the process by which the new 
‘invention’ is turned into an innovation when introduced to a market where it is put into use and 
thereby generates commercial value (Smith, 2010; Rothwell, 1994; Van de Ven, 1989; 
Schumpeter, 1939, 1934). How to put the innovation into use is thus tightly connected to how 
private firms commercialize their welfare innovations. However, new innovations often do not 
make it to the market and are therefore never put into use. Accomplishing this requires 
successful commercialization where the new innovations are diffused, and the prerequisite for 
this is the users’ and buyers’ adoption of the innovations (Smith, 2010; Hall, 2005). To explain 
why new innovations are not commercialized broadly in a market, the innovation literature often 
emphasizes the ‘not invented here’ (NIH) phenomenon (Katz and Allen, 1982). In the innovation 
literature, ‘not invented here’ (NIH) is known as a constraint on organizations’ capability to 
adopt new innovations (Cohen and Levinthal, 1990; Katz and Allen, 1982). Within healthcare in 
particular, NIH is typically described as dominant among health professionals who often tend to 
maintain a ‘we know best’ mindset, resulting in a NIH stance that constrains the adoption of 
external knowledge because internal knowledge is preferred (Chilingerian et al., 2005; McNeill, 
2013; Maccoby et al., 2013).  
 
In order to compensate for the neglect of research into commercialization of innovations 
developed through PPI, this article endeavors to investigate how firms seek to commercialize 
new welfare innovations. We do this by emphasizing the obstacles that some firms experience in 
their efforts to commercialize their products and services. Specifically, we focus on a group of 
firms that have stated that they have experienced a NIH stance on the part of Danish hospitals 
when seeking to commercialize their welfare innovations within Danish public healthcare. 
Therefore, the research question is: How do firms experience and respond to what they perceive 
as a NIH phenomenon at Danish hospitals when aiming to commercialize new welfare 
innovations?  
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This study investigates how firms engaged in PPI projects seek to commercialize welfare 
innovations within the healthcare system after developing these innovations in collaboration with 
public actors and selling these innovations to their direct public partners. As such, the study 
looks at the part of the commercialization process in which private firms have to bring their 
solution to the wider public healthcare market where a prerequisite for success is the users’ and 
buyers’ adoption of the new innovation (Smith, 2010; Hall, 2005). Also, as the study takes the 
perspective of the firms and elucidates their experience with and responses to the NIH 
phenomenon, we do not investigate the rationale involved in the rejection of new innovations 
from a public sector perspective.  
 
First, the theoretical framework is provided. The concept of PPI is explained through the 
theoretical lens of collaborative innovation literature. This includes theoretical concepts of 
networked governance combined with private firms’ networked commercialization, both 
emphasizing an outward-going innovation approach. In addition, NIH is briefly discussed to 
highlight why public and private actor collaboration remains challenging despite joint interests in 
collaborative innovation. Next, the research design is described arguing for the appropriateness 
of a multiple case study in which the main emphasis is on a case that clearly illustrates how a PPI 
firm experiences NIH while seeking to commercialize a welfare solution across Danish hospitals. 
Finally, we present and discuss our findings and draw our conclusions.  
 
 
Theory 
 
Current literature on PPI is mainly concerned with how to manage the development of 
new innovations, and it typically adopts a public management perspective (Evald, 2014). A 
considerable share of the literature relates to the practice of managing innovation processes that 
count on the participation of both public and private actors as public managers may experience 
barriers related to the actors’ lack of experience with such collaboration (Sørensen and Torfing, 
2012; Ansell and Gash, 2008). Public managers need to facilitate collaborative interaction and 
spur ideation in order to overcome the various barriers to collaboration throughout the 
development of a new innovation (Crosby and Bryson, 2010). What is just as important to 
explore - but has been neglected so far - is research into how firms that are engaged in PPI 
handle the commercialization of new innovations after these innovations have been developed 
through collaborative efforts counting both public and private actors (Evald, 2014). Addressing 
this call seems pivotal as firms often perceive commercialization as a challenging endeavor when 
they aim to commercialize and diffuse welfare innovations within Danish healthcare.  
 
There is no doubt that the most critical element in the innovation process is when new 
innovations are diffused and put into practical use in society through commercialization (Hall, 
2005; Van de Ven, 1989). In particular, private firms may see the commercialization process as 
inhibited because an NIH orientation in organizations may constrain the diffusion of new 
innovations across organizations in society (Katz and Allen, 1982). In order to identify key 
aspects about the NIH phenomenon, we will explore what lies behind the concept of NIH. First, 
however, networked governance and networked commercialization are explained as these 
approaches, which characterize both the public and private sector, are both directed by a network 
logic that is oriented towards an out-bound rather than an in-bound focus (Sørensen and Torfing, 
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2012; Vargo and Lusch, 2008). The term ‘logic’ here describes the taken-for-granted ways that 
organizations and individuals in society behave and organize (Friedland and Alford, 1991) and 
which seems to characterize the reasons why the actors engage in PPI. 
 
 
A network logic that guides co-creation of innovations across the public and private sector 
Throughout history, the development of new innovations has been characterized by 
complex processes involving interaction between different kinds of actors (Bijker, 1995). As 
such, new innovations are rarely developed in isolation from the external environment, but rather 
through interaction with different actors in society (Jæger, 2011). In accordance herewith, the 
public sector is oriented towards its external environment to enhance public innovation in 
healthcare. Through networked governance, the public sector employs cross-sector collaboration, 
partnerships, and other types of relationships between relevant actors. This may contribute to the 
development and diffusion of innovation in public policies and services (Sørensen and Torfing, 
2012; Eggers and Singh, 2009; Moore and Hartley, 2008). This networked approach has also 
characterized the development of innovation in the private sector where firms’ value creation and 
commercialization efforts have moved from a firm-centric focus to one of collaboration with 
actors (e.g. potential customers) in the external environment (Vargo and Lusch, 2008, 2004). 
Both the public and the private sector appear to be directed by a network logic that guides public 
and private organizations toward interaction with external actors. This is especially evident in the 
growing establishment of PPI projects. In the below table, the historical and recent development 
that both public sector organizations and private firms have experienced is summarized. 
Furthermore, the table presents a distinction (marked in red) between public organizations’ 
networked governance approach on the one hand and private firms’ networked 
commercialization approach on the other.  
 
Table 1: The networked governance approach versus the networked commercialization 
approach 
 
 Public organizations 
Shift from an inward orientation to networked 
governance 
Private firms 
Shift from an inward 
orientation to networked 
commercialization 
Approach Traditional 
bureaucracy  
New public 
management 
Networked 
governance 
Inward 
orientation 
Networked 
commercializa-
tion  
Charac-
teristic 
Rule-bound 
bureaucratic 
control focused 
on regulation  
Managerialism 
focused on 
market 
mechanisms  
Co-development 
through 
interaction with 
external actors 
Firm-centric 
focus on 
planned 
commercializati
on strategy 
Co-development 
and 
commercializa-
tion through 
interaction with 
external actors 
Note: Inspired by Ansell and Torfing (2014) and Vargo and Lusch (2008, 2004) 
 
Table 1 demonstrates that both the public and the private sector have developed from an 
in-bound focus on innovation to a network-oriented approach to innovation that is based on 
interactions with external actors. In general, then, enhancing public innovation in healthcare 
seems to be guided by a network logic that leads public and private actors towards mutual 
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collaboration. Thus, through the involvement in PPI projects, private firms are increasingly 
playing a central role in generating public innovation by developing new solutions that target 
public sector needs (Sørensen and Torfing, 2012; Borins, 2008). However, the historical 
developments that have edged the actors towards this network logic are very different for public 
and private organizations, respectively. 
 
The emergence of a networked governance approach for public organizations is related to 
the development of particular historical periods and ways of governing. The public sector found 
in Western democracies today is different from that found 30 years ago. The traditional 
bureaucratic form of governance, often termed Old Public Administration, was gradually 
supplemented and transformed by New Public Management (NPM) reforms in the 1980s and 
1990s. With a focus on managerialism, NPM is primarily based on the introduction of 
management techniques from the private sector and on an increased marketization of the public 
sector (Hood, 1991). The most recent variant of public governance, which is often termed New 
Public Governance, is focused on a networked governance approach concerned with external 
collaboration as opposed to the intra-organizational approach and the input and output focus of 
NPM (Hodge and Greve, 2010). 
  
In a similar manner to public sector organizations, the firms are guided by a network 
logic both in relation to the development of new innovations and in their attempts to 
commercialize these innovations. A network approach to commercialization is becoming 
increasingly dominant (Vargo and Lusch, 2008, 2004) and is oriented towards interaction with 
actors that are external to the firm. This stands in opposition to the in-bound focus that 
dominated firms in earlier decades. As such, firms’ commercialization of new innovations 
developed through PPI projects includes interaction with potential customers in the external 
environment throughout the firms’ commercialization activities (Chesbrough, 2003). The 
commercialization of innovations through interaction with external actors is characterized by 
initiating first sales and developing sales to multiple customers to profitably exploit what the 
firm produces (Aarikka-Stenroos et al., 2014; De Clercq and Voronov, 2011; Anderson et al., 
2010).  
 
What sometimes disrupts commercialization despite a seemingly common departure in a 
network logic is the prevalence of an NIH phenomenon. NIH is an obstacle to successful 
networked commercialization of new innovations, as it constrains the commercialization aspect 
of the innovations process (Katz and Allen, 1982) whereby new innovations are diffused and put 
into use by the customers and users (Hall, 2005; Van de Ven, 1989). NIH has been researched 
from the perspective of the organization influenced by NIH, e.g. in relation to knowledge sharing 
among individuals or projects dealing with an organization’s R&D activities (Lichtenthaler & 
Ernst, 2006; Michailova and Husted, 2003), organizations’ absorptive capacity and innovation 
culture (Herzog and Leger, 2010), and organization’s perspective towards open innovation 
(Chesbrough, 2006).  See Appendices 1 and 2 for a more detailed overview of the characteristics 
of NIH in the innovation literature. Common to all is, however, is an understanding that NIH is 
an attitude-based bias towards knowledge (e.g. new ideas and innovative technologies) derived 
from a source or contextual background that is external to the organization, group, or individual 
(Katz and Allen, 1982; Kostova and Roth, 2002). As such, individuals have a generally negative 
attitude towards knowledge, ideas, or technologies of external origin (Burcharth et al., 2014; 
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Bohner and Dickel, 2011). In explaining NIH, much literature draws on social psychology that 
focuses on rejection behaviors of individuals and groups (Pillar, 2014). Some key examples of 
different terms used in the literature to describe NIH are: ‘Not invented here’ syndrome, ‘not 
invented here’ attitude, and ‘not invented here’ mindset. In particular, health professionals such 
as doctors and nurses may be skeptical about adopting an innovation from an external source 
because they may be dominated by a ‘we know best’ mindset (Chilingerian et al., 2005; McNeill, 
2013; Maccoby et al., 2013; Trusko et al., 2013). This may be due to health professionals’ 
responsibility for people’s lives and well-being which possibly causes them to rely more on their 
own expertise. This mentality may produce an NIH phenomenon which inhibits the adoption of 
new innovations or knowledge developed ‘outside’ the organization. This happens despite a 
common rooting in a network logic that paves the way for collaborative innovation partnerships. 
So even though more and more welfare innovations are developed through collaborative 
innovation projects across the public and private sector (Sørensen and Torfing, 2012; Vargo and 
Lusch, 2008), challenges remain when it comes to diffusing and commercializing jointly 
developed welfare solutions. How firms deal with this will be the focus of the rest of the article. 
We focus on how a group of firms expresses their experience of an NIH orientation at Danish 
hospitals and how they respond to this in their efforts to find a way to diffuse and commercialize 
their solutions.  
 
 
Research design 
 
We selected a multiple case study approach for this study. The cases are four PPI projects 
that all focus on developing welfare innovations targeting Danish public healthcare. 
Comprehensively exploring a few specific cases seems appropriate as this generates a wealth of 
information about the phenomenon in focus (Miles and Huberman, 1994). Through the multiple 
cases, the study aims to provide a rich in-depth understanding (Eisenhardt and Graebner, 2007) 
of PPI firms’ experience of NIH while they endeavor to commercialize welfare innovations in 
the specific empirical settings of healthcare. Furthermore, the multiple case study approach is 
particularly suitable when phenomena are investigated in their natural environments and where 
the phenomenon under investigation is difficult to isolate from its surroundings (Yin, 2003); and 
because the investigation of firms’ experience of NIH cannot be separated from the surroundings 
in which they manifest themselves, a multiple case study appears the most appropriate method.  
 
The four case studies are embedded in the context of Danish public healthcare. Since the 
national structural reform of 2007, Danish healthcare has consisted of 5 regions which have 
responsibility for the Danish hospitals and 98 municipalities responsible for the prevention and 
rehabilitation of patients following discharge from hospital. In relation to the structural reform, 
plans were made to reduce the number of hospitals and to allocate considerable financial 
resources to building sizable new hospitals within the next decade (Ministry of Interior and 
Social affairs, 2009). The processes related to the building of new hospitals have triggered 
numerous PPI projects. Table 2 provides an overview of the four cases.  
 
Among the four cases, Case 1 was selected as an extreme example that may serve to 
provide an in-depth illustration of how a commercializing PPI firm experiences and responds to 
what is perceived as an NIH phenomenon at Danish hospitals. Specifically, the case was selected 
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because it generates rich process information about the studied phenomenon (Flyvbjerg, 2006) 
and promises to provide greater detail about the phenomenon in question than the other cases 
would (Siggelkow, 2007). The phenomenon in focus is NIH which hampers the firm in case 1 
from commercializing broadly in Danish healthcare. The three other cases serve to further 
illustrate the experiences derived from Case 1. 
 
Table 2: Four cases in which NIH is experienced by PPI firms  
 
PPI projects  Firms’ business area Firm 
size* 
Case 1 
Development of a telemedicine solution aiming to 
provide treatment and monitoring of a hospital’s chronic 
obstructive pulmonary disease (COPD) patients from 
their homes following their discharge from the hospital. 
The public project partner was a hospital.  
Manufacturer of healthcare 
products whose main focus is on 
telemedicine solutions. 
Small 
Case 2 
Development of a self-propelled person lifter for heavily 
overweight patients in hospitals. The public project 
partner was a hospital.  
Manufacturing of healthcare 
products with a primary focus 
on lifts. 
Small 
Case 3 
Development of a series of product concepts for 
standard hospital and nursing beds used by bed-ridden 
patients/residents at municipal nursing homes. The 
public project partner was a municipality.   
Designing and manufacturing 
electric linear actuator solutions. 
Large 
Case 4 
Development of a telemedicine solution for virtual 
home visits at the homes of patients with chronic 
obstructive pulmonary disease (COPD) after their 
discharge from the hospital. The public project partners 
were a hospital and a municipality.  
Provides services within 4 areas 
of business: assistance, rescue, 
healthcare and training.  
Large 
*NOTE: The classification of the size of the firms is based on the European Union’s legislation on SME. Small 
firms have less than 50 employees, medium firms have less than 250, and large firms over 250 (Commission 
Recommendation of 6 May 2003 concerning the definition of micro, small and medium-sized enterprises 
(2003/361/EC. Official Journal of the European Union, L 124/36). 
 
Case selection strategy 
In 2014, the number of PPI projects amounted to over 250 and the majority of these, 177 
projects, were established within Danish healthcare (Brogaard and Petersen, 2014). The four 
cases were selected from the pool of 177 completed PPI projects that all focused on developing 
welfare innovations targeted at the Danish public healthcare. They were chosen as they fulfilled 
the following criteria (1) the firms in the cases intended to initially commercialize the 
innovations developed through the PPI projects broadly within Danish healthcare by interacting 
with public actors at different hospitals, (2) the firms expressed explicitly themselves and on 
their own initiative that they had experienced a ‘not invented here’ (NIH) orientation at Danish 
hospitals, when seeking to commercialize their welfare innovations across hospitals, and (3) in 
response to NIH these firms have reshaped their practices and have succeeded in 
commercializing their welfare innovations internationally. The third criterion minimizes the 
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possibility that the innovative solutions are not relevant and thus helps ensure that innovations 
are rejected due to NIH. 
 
Data collection 
In order to strengthen the accuracy of the case study findings, multiple data sources were 
used. The primary data collection was based on semi-structured interviews. In addition hereto, 
project reports and documents from the four PPI projects were scrutinized and information about 
the projects was acquired through participation in PPI seminars and also conferences held in 
Denmark that disseminated more general knowledge about PPI. Also, public documents about 
welfare innovation were used to support the findings (e.g. from each of the 5 regions and Danish 
Regions which is the interest organization for the 5 regions in Denmark). 
 
The semi-structured interviews were conducted with key public and private actors 
engaged in the four cases. Interviews with the 4 firm actors were conducted at the firms’ 
headquarters and included open-ended questions about the innovation process in the PPI 
projects, particularly those with a focus on the firms’ commercialization of welfare innovations. 
An additional interview was conducted with the managing director of the firm in the 
aforementioned extreme case (Case 1), and an additional visit to the firm’s headquarters was 
made where (unrecorded) conversations took place. Additionally, interviews were conducted 
with public health professionals (a head of department and hospital manager) at the hospital 
where the welfare innovation from Case 1 had been developed and implemented. Finally, an 
interview was conducted with a doctor working at the hospital where the firm in Case 1 
experienced NIH while aiming to commercialize the welfare innovation (Appendix 3 provides an 
overview of the interviews). Each interview lasted for about 1½ hours and was recorded, 
transcribed, and coded. To support the coding of the transcripts, the software program NVivo 
was used. Identifiable topics or themes related to the research question have been labeled as a 
way of guiding the analysis and coding the transcripts (Miles and Huberman, 1994), such as 
‘constraint to commercialize’. Coding makes it possible to systematically derive characteristics 
about the firms’ commercialization and the experience of NIH by coding/labeling text passages, 
phrases or words in the interview transcripts (Appendix 3 provides an overview of the coding 
results for the four cases).  
 
 
Findings 
 
Case 1 serves as an extreme case that provides an in-depth understanding of how a firm 
experiences NIH in Danish healthcare over time as it aims to commercialize a new welfare 
innovation developed in the context of a PPI project. Furthermore, findings from all four cases 
illustrate that the PPI firms ultimately reshape their commercialization practices in response to 
experiencing NIH. Specifically, the firms in the four cases (including the extreme case) become 
increasingly internationally oriented as they encounter NIH.  
 
The story of the extreme case – Case 1 
Case 1 consists of a PPI project that focused on developing telemedicine for patients with 
chronic obstructive pulmonary disease (COPD). The telemedicine solution allows hospitals to 
provide treatment and monitoring of their COPD patients in their own homes. The project period 
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lasted for three years while the telemedicine solution was developed. The firm that engaged in 
the project was founded in 2002 as a spin-off of an existing IT firm. The firm’s project partner 
was a Danish hospital located within the same region (the Region of Southern Denmark) as the 
firm. The project was partly financed through public funding, by the hospital, and by the firm. In 
total, the financial costs in the project accrued to 6-10 million Danish kroner (about 1 million 
Euros) of which 1.2 million Danish kroner were public funding (Danish Business Authority, 
2009).  
 
During the stage of the innovation process in which the telemedical solution was 
developed, the firm made contact with national Danish politicians. The firm intended to lobby 
for a change in the national law regarding the financial rates, which each hospital receives from 
the state when patients are hospitalized. The firm’s desire for a statutory change was related to its 
aim to commercialize to multiple Danish hospitals and to the diffusion of its telemedicine 
solution. In the course of the firm’s efforts, it was realized that it was necessary to increase the 
hospitals’ incentive to implement telemedicine solutions. The firm therefore aimed to ensure that 
hospitals would receive financial compensation when providing treatment and monitoring of 
their COPD patients in their own homes. Among others, the Minister of Health visited the firm 
after the telemedicine solution had been tested and documentation of the time-saving benefits, 
etc., had been prepared. Eventually, a law change was passed by the national assembly.  
 
In the course of the firm’s interaction with the politicians, it focused on the possibility of 
commercializing the telemedicine solution broadly to multiple hospitals as it aimed to enhance 
their incentive to purchase and implement telemedicine solutions. The firm focused on broad 
commercialization within the healthcare system and on generating commercial value from the 
welfare innovation being developed in the PPI project: We only engage in a project when we see 
some real possibilities…When we are at the end of a project period and calculations are made, 
then there is one thing that dominates above all, and that is economy. 
 
After the project period had concluded, the hospital that was the firm’s project partner 
purchased the telemedicine solution from the firm and implemented it at the hospital. 
Subsequently, the firm put efforts into commercializing the telemedicine solution to other Danish 
hospitals, but did not succeed in doing so. The firm made contact with several hospitals across 
various Danish regions and presented test documentation related to the benefits of implementing 
the product (e.g. time-saving benefits). Throughout the firm’s commercialization activities, it 
experienced NIH as it interacted with health professionals. There appeared to be a general 
tendency of rejection towards the new product: When you get out to a hospital outside the region 
and tell them about this product, they say that it sounds good, but this is not how they treat their 
patients... They want to give them a treatment based on their own invention, and that’s how it is. 
Every region has initiated a project concerned with COPD, whether it is a touch screen or a box 
or whatever. Everyone has done it later (than us), but no one will buy something that works, 
because you want to invent it yourself.  
 
The firm did not succeed in commercializing broadly by diffusing the telemedicine 
solution across hospitals within Danish healthcare. To illustrate this commercialization challenge 
more comprehensively, one commercialization activity is exemplified. This activity is focused 
on one of the hospitals where the firm attempted to commercialize the telemedicine solution.  
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
11 
 
The firm made an arrangement with a hospital situated in another Danish region. The 
firm gave the hospital the opportunity to use the telemedicine solution for free during a two-
month trial period. The firm did this to allow the hospital to try out the product before deciding 
on a purchase. However, the hospital did not subsequently purchase the telemedicine solution. 
Instead, the hospital eventually initiated its own three-year PPI project aiming to develop a 
similar telemedicine solution targeting COPD patients. The firm explains this in the following 
statement: I tried to offer the product for free to this hospital for six months in order to gain 
access to the hospital. Subsequently, they developed something by themselves. This just proves 
that it is not about that – it is because they want the recognition for their own work. They do not 
want to buy something made in our region. 
 
The PPI project initiated by the hospital in the other region is the project described in 
Case 4. The large firm involved in this project also experienced commercialization challenges as 
it was constrained in commercializing broadly during the PPI project period. The reason for this 
was related to a doctor from the hospital involved in the PPI project. This doctor was concerned 
with keeping the knowledge in the PPI project inside the boundaries of the project and did not 
want to share knowledge with other hospitals during the project period. The doctor thereby 
restricted the firm’s potential of contacting other hospitals to commercialize through a network 
approach by making contact to potential customers. The doctor explains that he had a discussion 
with the firm that was engaged in the project regarding its contact to other hospitals: It is 
something which has been a bit of a challenge because it is a private organization which has to 
make money. So, of course, they have been trying to see if they could sell it [the telemedicine 
solution] in other places. And there was a time where we had a small dispute about this… ‘Are 
you benefitting from the effort and ‘heart blood’ we have put into this project, and then maybe 
you begin to sell it elsewhere…’ So, we had to talk about setting up up some rules of the game 
about this. And then we have talked openly about it. 
 
The doctor seemed concerned with not sharing the knowledge generated in the PPI 
project. As such, NIH does not just relate to rejecting the implementation of innovations and 
knowledge from external sources; it is also limits sharing of innovations or knowledge with 
others – at least during the period in which the new innovation is being developed.  
 
This lack of knowledge sharing in relation to welfare innovations seems to be 
acknowledged by the Danish Regions, a central organization comprising all the five regions in 
Denmark: The regions are good at being innovative when it comes to new effective solutions. But 
the regions are less apt at using other regions’ innovativeness (Danish Regions, 2014). 
 
The reason for the lack of knowledge sharing is explained by the presence of a certain 
culture within the healthcare system; one that is associated with the prestige and legitimacy of 
being the prime supplier of new knowledge: There is a long tradition within healthcare to 
connect the role as a knowledge supplier with high prestige and authority. It is a part of the 
culture that the ones who are in front with knowledge are the best (Danish Regions, 2014). 
 
The hospital in the other region than the firm in Case 1 used the slogan ‘Being on the 
forefront of health’ at the hospital’s webpage in relation to a description of the PPI project where 
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the similar telemedicine solution was being developed. This phrase appears to be an indirect way 
of positioning the hospital as a frontrunner in the development of welfare innovations in 
healthcare rather than adopting them from other hospitals. As such, the wish to ‘be on the 
forefront” may limit adoption of welfare innovations developed elsewhere.  
 
Eventually, the firm in Case 1 focused on export and changed its commercialization 
practice. Instead of interacting with Danish hospitals, it started to explore alternative avenues and 
to investigate the structural set-up of healthcare systems in other countries. A year after the 
project period concluded, the firm succeeded in initiating its first international sale as it 
commercialized the telemedicine solution to a Norwegian hospital. Subsequently, the firm 
commercialized the telemedicine solution to more hospitals within Norwegian healthcare and it 
also started to focus on the British healthcare system. Thus, the firm’s commercialization 
practice was eventually reshaped in response to the experience of NIH in Danish healthcare. 
 
Supporting evidence from the illustrative cases – Cases 2, 3 and 4 
In the three illustrative cases, the PPI firms also experienced NIH, and this appears to 
have influenced the firms’ commercialization practices. Like the firm in Case 1, those in the 
other cases responded to NIH. Specifically, most firms began focusing on international markets 
different from those encountered in Danish healthcare. For example, the small firm in Case 2 
stated: What goes wrong in the process, this is clear, is that the Danish health care sector does 
not follow up on implementation and commercialization when an innovation has been developed. 
This means that we end up selling our innovation internationally.  
 
Also, Cases 3 and 4 are internationally oriented with respect to commercialization of PPI 
solutions. For example, the firm in Case 3 stated: And the export sale grows. Where we used to 
have more sales in Denmark and our first thought always was that we needed to cover the whole 
country before we did anything else, then now our board says that it is too complicated in 
Denmark and we need to export.  
 
This is in line with the firm in Case 4 that states: We use the knowhow gained in Denmark 
to export internationally.  
 
However, in comparison to the smaller firms (Cases 1 and 2), the two large cases (3 and 
4) appear to be primarily focused on using PPI projects in Denmark as experimental test settings 
before focusing on export. In contrast, the smaller firms appear more eager to export their 
solutions at a faster pace. As smaller firms tend to possess fewer resources than larger firms, the 
firms in Cases 1 and 2 may be more dependent on rapid commercialization of their PPI solution.  
 
 
Discussion 
 
Innovation processes are initiated when a new idea is being developed and generates 
commercial value (Twiss, 1992). Innovation processes therefore embrace both the development 
and the commercialization of a new innovation. The new welfare innovations presented in the 
four cases all originate from new inventions that are transformed into innovations through 
collaboration between public and private actors in PPI projects, spurring potential value for 
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citizens, public servants, and private firms. Furthermore, a primary focus of the study was on 
firms’ commercialization of welfare solutions co-created with public actors. Specifically, we 
followed closely how firms seek to generate commercial value from their new welfare 
innovations. The findings suggest that challenges exist in relation to the commercialization 
aspect of the innovation process. 
 
The PPI firms experience an NIH phenomenon that restricts the commercialization of 
welfare innovations across Danish hospitals. Moreover, our findings indicate that the firms 
perceive the NIH phenomenon as counter-intuitive as there is an expressed need for new welfare 
innovations in the national agenda due, among others, to the demographic challenges associated 
with an aging population (Klitkou, 2011). This societal challenge was characterized as a ‘wicked 
problem’ which cannot be solved by a single actor alone because of its complexity (Rittel and 
Webber, 1973); hence, PPI has been introduced repeatedly in the Danish healthcare sector. 
 
Despite the prevalence of a network logic across the public and private sector, the 
multiple case study gives important insight into why some firms may not succeed in diffusing 
their welfare innovation to different hospital contexts. Rather, the firms respond to NIH by 
becoming more internationally-oriented as they explore the opportunities for exporting their 
welfare solution. Case 1, in particular, showed proof of substantial changes in the firm’s strategic 
commercialization focus. Instead of managing relations to key public actors at well-known 
hospitals in the home market, the firm eventually started focusing on the identification of other 
international healthcare markets and key actors at international hospitals in order to build new 
networks. Thus, the firm still maintained a network approach to commercialization through 
identification and interaction with potential customers (Håkansson et al. 2009). However, these 
are now located beyond the home market, within healthcare systems that are less familiar to the 
firm. It eventually succeeded in commercializing to international healthcare systems. The shift in 
the firm’s focus was particularly noticeable in the continuous change in the firm’s daily 
commercialization practices, which eventually became dominated by the accumulation of 
knowledge about other healthcare systems based on travels, particularly to British hospitals, and 
international healthcare exhibitions and conferences (e.g. the American ‘Future of Health Care’ 
conference in Silicon Valley). The experience documented in the extreme case is further 
supported by the three illustrative cases as their experience of NIH and their reactions to NIH 
were quite similar to those of the extreme case firm. All of the firms change their 
commercialization practice by focusing on measures aiming to export their welfare solutions to 
an international market. As such, the firms’ response to NIH indicates that welfare innovations 
developed in PPI projects may create export opportunities for private firms if they are capable of 
reshaping their commercialization practices.  
 
It is only fair to mention that from a hospital’s perspective there may be a logical 
rationale for the rejection of a welfare innovation developed elsewhere in the healthcare sector if 
the innovation does not fit into the hospital’s context. As organizations are different and 
contingent upon the local context in which they are situated (Scott, 2003), each hospital in the 
healthcare system is different in regard to location, practices, organizational culture, etc. 
Therefore, health professionals may reject new welfare innovations simply because the 
innovation is not in line with prevailing standards and practices at a specific hospital. As such, it 
is not only the origins of new innovations that determine if it becomes successful, but also the 
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context in which the innovative product or service is implemented (Roberts and King, 1996). 
Naturally, private firms may have to consider this when developing new welfare solutions. To 
take an example, in Case 1, the PPI firm focuses on commercializing a standardized welfare 
innovation across hospitals within the healthcare system, and not on adapting the welfare 
innovation to fit different hospital contexts. This may well explain why the firm experiences an 
NIH phenomenon. However, it seems possible for firms in general to adapt specific welfare 
innovations to specific hospitals, but the point is how private firms react to the challenges they 
face. Based on this multiple case study, the firms react to the prevalence of a NIH phenomenon 
by reshaping their commercialization practices as they search for other opportunities to diffuse 
and commercialize their solutions. As firms decide to respond in this manner, the Danish 
healthcare system may risk ‘losing’ central welfare innovations if similar innovations are not 
developed through another PPI project, as seen in Case 1. Therefore, welfare innovations may be 
exported instead of being put into use in the home market where they could well enhance public 
innovation in healthcare and create public value. 
 
Nevertheless, hospitals’ rejection of new welfare innovations developed elsewhere does 
not seem to place limits upon their use of networked governance, as manifested in the 
establishment of new PPI projects. As illustrated in Case 1, two similar welfare innovations were 
developed across hospital contexts through the use of PPI projects. The hospital which rejected 
the purchase and adoption of the firm’s welfare innovation subsequently initiated its own PPI 
project where a similar welfare innovation was developed. The doctor engaged in the PPI project 
at this hospital focused on keeping the knowledge inside the boundaries of the project during the 
project period. As a result, the firm involved in the project was restricted from initiating 
commercialization activities and thus restricted from sharing knowledge about the new welfare 
innovation across hospitals in order to initiate the first sales. This runs contrary to the networked 
approach that firms have to engage in commercialization where they interact with multiple 
potential customers during the development process (Clarke et al., 2015). 
 
It can be assumed that the hospital wanted to appear to be a prime knowledge supplier of 
new welfare innovations, which is rooted in a ‘we know best’ mindset (Chilingerian et al., 2005). 
It positioned itself as a ‘forerunner’ when it comes to developing new welfare innovations, which 
indicates a need to appear to be a prime knowledge supplier. This need may derive from an 
institutional pressure in society related to an increasing focus on public innovation and the need 
to be innovative in order to solve some of society’s ‘wicked’ problems. The field of healthcare 
appears to be influenced by an institutional pressure relating to normative societal expectations 
(Mizruchi and Fein, 1999; DiMaggio and Powell, 1983). Over the past decade, the political focus 
on the public sector’s need to be innovative has grown intensely (Ansell and Torfing, 2014). As 
such, there seems to be societal expectations that public healthcare organizations should be 
innovative. This may precipitate a mindset according to which hospitals want to appear to be the 
most innovative or a ‘forerunner’.  
 
 
Conclusion and implications 
 
This article contributes to collaborative innovation literature focused on the enhancement 
of public innovation through the use of cross-sector collaboration such as PPI projects. There is a 
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lack of research on how private firms seek to commercialize new innovations with a view to 
creating public innovation in practice across organizations in society (Evald, 2014) and how they 
experience and respond to the commercialization process. We emphasize commercialization as a 
central aspect of the innovation processes. Innovation processes also include commercialization 
whereby new innovations gain commercial success through diffusion across organizations in 
society (Van de Ven, 1989; Schumpeter, 1939), and the present study indicates that firms face 
commercialization challenges. The firms experience an NIH phenomenon that constrains the 
diffusion of welfare innovations across Danish hospitals, where they could be put into practical 
use to enhance public innovation. The study also shows that PPI firms manage to commercialize 
welfare innovations internationally by reshaping their commercialization practices.  
 
To summarize, as exemplified through an extreme case and three illustrative cases, the 
findings show: 1) how NIH is experienced by firms that aim to commercialize welfare 
innovations developed through PPI projects. The firms’ experience of NIH is backed by the 
innovation literature that states that an NIH orientation exists, particularly among healthcare 
professionals. 2) Moreover, our findings demonstrate that the firms seem to reshape their 
commercialization practice in response to NIH as their networked commercialization activities 
become internationally oriented instead of home-market oriented. Future research is warranted 
on the commercialization of public sector innovations developed through cross-sector 
collaboration in other fields than healthcare. The energy industry is a potentially interesting field 
of study in this context as this policy area that has gained increasing political attention in the 
national and EU agenda, which is analogous to the development of new welfare innovations. 
 
The implications of our findings for the public sector may be summarized as knowledge 
sharing challenges. A central recommendation to public managers and policy makers dealing 
with public innovation is to create spaces where multiple public and private actors may connect 
and share knowledge about new ideas and innovative products or services. Such spaces may be 
created by establishing consortia formation requirements in larger PPI projects that include 
various Danish regions. Public actors may benefit from forming consortia across regions and/or 
hospitals as this may enhance the possibility for knowledge sharing and the opportunity to learn 
from other public organizations. It may also enhance joint ownership of new welfare innovations 
across hospitals and health professionals, which may help reduce the desire to develop ‘one’s 
own’ welfare innovation – innovations that are similar to the already existing ones. Moreover, 
the involvement of multiple firms in PPI project consortia may enhance knowledge spill-over 
between firms – for instance between those with little experience with PPI in healthcare and 
those which have been engaged in a portfolio of PPI projects. In particular, small firms may 
benefit from larger firms’ access to established knowledge pools in well-established networks 
(e.g. in the healthcare industry), while larger firms may benefit from small firms’ innovativeness 
(Colombo et al., 2006). 
 
Based on our findings, a central recommendation to firm managers is to develop an 
awareness of the environment in which their potential public customers are situated. In this 
study, the NIH phenomenon is evident in the Danish hospital environment. NIH seems to be 
rooted in a ‘we know best’ mindset, and the prestige associated with being a prime knowledge 
supplier ultimately seems to shape and the hospitals’ predilection for local PPI projects. A key 
implication for PPI firms is that managers need to learn about more intangible aspects (such as 
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NIH), which could be influencing potential public customers’ attitudes towards new innovations. 
This knowledge may be achieved through a long learning process involving continuous 
interaction and development of multiple cross-sector networks with key public actors including 
health professionals, hospital managers, politicians, etc. As such, it may be beneficial for firms to 
engage more in public networked governance and participate in multiple PPI projects.   
 
 
About the authors 
Helle Aarøe Nissen is a PhD student and researcher at the Department of 
Entrepreneurship and Relationship Management, University of Southern Denmark. Her research 
interests are in the areas of public private innovation, networks, innovation processes, and 
commercialization of innovations in the public sector. She has previously published in Industrial 
Marketing Management and International Public Management Review. The author can be 
reached at the email address: hani@sam.sdu.dk  
Majbritt Rostgaard Evald is an Associate Professor at the Department of 
Entrepreneurship and Relationship Management, University of Southern Denmark. Her research 
is mainly focused on intrapreneurship with particular interest in how exploitative and explorative 
innovation activities can be mixed in a balanced way. She has published several international 
articles in the field of entrepreneurship and innovation in journals such as: Journal of Business 
Venturing, Industrial Marketing Management, International Journal of Entrepreneurship and 
Innovation Management, European Management Journal, and Journal of International 
Entrepreneurship. The author can be reached at the email address: mre@sam.sdu.dk 
Ann Højbjerg Clarke is an Associate Professor and Head of Department at the 
Department of Entrepreneurship and Relationship Management, University of Southern 
Denmark. She researches in the field of business-to-business marketing and innovation. She has 
published in the areas of segmentation, portfolios, business models, open innovation, 
networking, spin-off companies, corporate venturing, and public private innovation. She has 
published in journals such as Journal of Business to Business Marketing, Industrial Marketing 
Management, European Journal of Marketing, European Management Journal, Advances in 
Business Marketing and Purchasing, and International Journal of Entrepreneurial Venturing. The 
author can be reached at the email address: ahc@sam.sdu.dk 
 
References: 
 
Adarves‐Yorno, I., A. Haslam & T. Postmes. 2008. And now for something completely 
different? The impact of group membership on perceptions of creativity. Social Influence, 3(4): 
248-266. 
 
Ansell, C. & J. Torfing. 2014. Collaboration and design. New tools for public innovation pp. 1-
19 in Ansell, C. and Torfing, J. (eds.), Public Innovation through Collaboration and Design. 
New York, NY: Routledge.  
 
Asllani, A. & A. Lari. 2011. Open innovation modeling using game theory. Academy of 
Information and Management Sciences Journal, 14(2): 79-90. 
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
17 
 
Antons, D. & F. Pillar. 2015. Opening the Black Box of "Not-Invented-Here": Attitudes, 
Decision Biases, and Behavioral Consequences. Academy of Management Perspectives, 29(2): 
193-217. 
 
Barley, S. R. & P. S. Tolbert. 1997. Institutionalization and structuration: Studying the links 
between action and institution. Organization Studies, 18(1): 93-117. 
 
Bessant, J. 2008. Dealing with discontinuous innovation: The European experience. 
International Journal of Technology Management, 42(1/2): 36-50. 
 
Bijker, W. E. 1995. Of bicycles, bakelites, and bulbs: toward a theory of sociotechnical change. 
Cambridge, MA: MIT Press. 
 
Bohner, G. & N. Dickel. 2011. Attitudes and Attitude Change. Annual Review of Psychology, 62: 
391-417. 
 
Brogaard, L. & O. Petersen. 2014. Overview of public private innovation partnerships in 
welfare. Copenhagen, DK: KORA. 
 
Borins, S. 2008. Innovations in Government. Washington, D.C.: Brookings Institution Press. 
 
Buenstorf, G. & M. Geissler. 2012. Not invented here: technology licensing, knowledge transfer 
and innovation based on public research. Journal of Evolutionary Economics, 22(3): 481-511. 
 
Burcharth, A., L. A., M. P. Knudsen & H. A. Søndergaard. 2014. Neither invented nor shared 
here: The impact and management of attitudes for the adoption of open innovation practices. 
Technovation, 34(1): 149-161. 
 
Chiesa, V. & F. Frattini. 2011. Commercializing technological innovation: Learning from 
failures in high-tech markets. Journal of Product Innovation Management, 28(4): 437–454. 
 
Cheng, M. & M. Wang. 2008. Social networks and a new venture’s innovative capability: the 
role of trust within entrepreneurial teams. R&D Management, 38(3): 253–264. 
 
Chesbrough, H. & A. Crowther. 2006. Beyond high tech: early adopters of open innovation in 
other industries. R&D Management, 36: 229–236. 
 
Cohen, W. & D. Levinthal. 1990. Absorptive Capacity: A New Perspective on Learning and 
Innovation. Administrative Science Quarterly, 35(1): 128-152. 
 
Colombo, M., L. Grilli & E. Piva. 2006. In search of complementary assets: The determinants of 
alliance formation of high-tech start-ups. Research Policy, 35(8): 1166-1199. 
 
Center for Public Innovation. 2014, July. Public Innovation. On the edge, into the core, over to 
the neighbor. Center for Public Innovation, Copenhagen, DK. 
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
18 
 
Chilingerian, J., G. Savage, M. Powell & Q. Xiao. 2005. Preface: A Framework for the 
Developing Field of International Health Care Management pp. 18-25 in Grant T. Savage, Jon A. 
Chilingerian, Michael Powell, Qian Xiao (eds.) International Health Care Management 
(Advances in Health Care Management, Volume 5). Bingley, UK: Emerald Group Publishing 
Limited. 
Crosby, B. C. & J. Bryson. 2010. Integrative leadership and the creation and maintenance of 
cross-sector collaboration. The Leadership Quarterly, 21(2): 211-230. 
 
Clarke, A., M. Evald & L. Aarikka-Stenroos. 2015. Evolvement of commercialization plans 
through interaction with multiple stakeholders - Patterns identified from Public-Private 
Innovation Projects. Industrial Marketing and Purchasing (IMP) conference: Kolding, DK, 
September.  
 
Danish Regions. 2014. Reuse is the key word in knowledge sharing. Accessed January 8, 2015 at 
http://www.regioner.dk/sundhed/videnspredning+i+sundhedsv%C3%A6senet/genbrug+er+n%C
3%B8gleordet+i+videnspredning  
 
Danish Regions. 2010. Health innovation and firm collaboration. Danish Regions publication, 
2010.  
 
Danish Business Authority. 2009. Analysis of public private collaboration on innovation. 
Publication from the Danish Business Authority: Copenhagen, DK, March 2009. 
 
de Clercq D. & M. Voronov. 2011. Sustainability in entrepreneurship: A tale of two logics. 
International Small Business Journal, 29(4): 322-344. 
 
Dealtry, R. 2008. Exploration of a contextual management framework for strategic learning 
alliances. Journal of Workplace Learning, 20(6): 443 – 452. 
 
DiMaggio, P. J. & W. Powell. 1983. The iron cage revisited. Institutional isomorphism and 
collective rationality in organizational fields. American Sociological Review, 48: 147-60. 
 
Dunn, M. B. and C. Jones. 2010. Institutional logics and institutional pluralism: the contestation 
of care and science logics in medical education, 1967-2005. Administrative Science Quarterly, 
55: 114–149. 
 
Evald, M. R., H.A. Nissen, A. H. Clarke & K. B. Munksgaard. 2014. Reviewing cross-field 
Public Private Innovation literature: Identifying research fields, terminologies and current and 
future research themes. International Public Management Review, 15(2): 1-26. 
 
Eisenhardt, K. M. 1989. Building theories from case study research. Academy of Management 
Review, 14(4): 532-550. 
 
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
19 
Eisenhardt, K. M. & M. E. Graebner. 2007. Theory building from cases: opportunities and 
challenges. Academy of Management Journal, 50(1): 25–32. 
 
Friedland, R. & R. R. Alford. 1991. Bringing society back in: Symbols, practices, and 
institutional contradictions pp. 232-263 in Powel, W.W. & DiMaggio, P.J. (eds.), The new 
institutionalism in organizational analysis. Chicago, IL: University of Chicago Press. 
 
Ford, C. 1996. A Theory of Individual Creative Action in Multiple Social Domains. The 
Academy of Management Review, 21(4): 1112-1142. 
 
Gassmann, O. 2006. Opening up the innovation process: towards an agenda. R&D Management, 
36: 223–228. 
 
Greiner, M. & R. M. Franza. 2003. Barriers and Bridges for Successful Environmental 
Technology Transfer. The Journal of Technology Transfer, 28(2): 167-177. 
 
Griffin, A. & J. R. Hauser. 1996. Integrating R&D and Marketing: A Review and Analysis of the 
Literature.” Journal of Product Innovation Management, 13: 191–215. 
 
Hall, B. H. 2005. “Innovation and Diffusion.” Pp. 459-486 in J. Fagerberg, D. C. Mowery, and 
R. R. Nelson (eds.), The Oxford Handbook of Innovation. New York, NY: Oxford University 
Press.  
 
Hauser, J. R. 1998. Research, Development, and Engineering Metrics. Management Science, 
44(12): 1670-1689. 
 
Herzog, P. & J. Leker. 2010. Open and closed innovation – different innovation cultures for 
different strategies. International Journal of Technology Management, 52(3/4): 322-343. 
 
Hodge, G. & Greve, C. 2010. Public-private partnerships and public governance challenges pp. 
149-162 in Osborne, S. (ed.), The New Public Governance? London, UK: Routledge. 
 
Håkansson, H., D. Ford, L.E. Gadde, I. Snehota & A. Waluszewski. 2009. Business in Networks. 
Chichester, UK: Wiley & Sons. 
 
Hood, C. 1991. A public administration for all seasons? Public Administration, 69(1): 1-19. 
 
Jæger, B. 2011.User-driven innovation in the public sector. Pp. 151-169 in C. J. Kristensen and 
S. Voxsted (eds.), Innovation and entrepreneurship. Copenhagen, DK: Hans Reitzel Publishing.  
 
Kathoefer, D. G. & J. Leker. 2010. Knowledge transfer in academia: an exploratory study on the 
Not-Invented-Here Syndrome. The Journal of Technology Transfer, 37(5): 658-675. 
 
Katz, R. & T. J. Allen. 1982. Investigating the Not Invented Here (NIH) syndrome: A look at the 
performance, tenure, and communication patterns of 50 R & D Project Groups. R&D 
Management, 12: 7–20. 
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
20 
 
Kickert, W. J. M., E.-H. Klijn & J. F. M. Koppenjan (Eds). 1997. Managing Complex Networks. 
London, UK: Sage. 
 
Klitkou, A. 2011. Mini Country Report/Denmark. Thematic Report 2011 under Specific Contract 
for the Integration of INNO Policy TrendChart with ERAWATCH (2011-2012). December 
2011. 
 
Leximancer. 2011. Leximancer Manual - version 4. www.leximancer.com  
 
Lichtenthaler, U. & H. Ernst. 2006. Attitudes to externally organising knowledge management 
tasks: a review, reconsideration and extension of the NIH syndrome. R&D Management, 36: 
367–386. 
 
Lichtenthaler, U., H. Ernst and M. Hoegl. 2010. Not-Sold-Here: How Attitudes Influence 
External Knowledge Exploitation. Organization Science, 21(5): 1054-1071. 
 
Lilleoere, A. M. & E. H. Hansen. 2011. Knowledge-sharing practices in pharmaceutical research 
and development-a case study. Knowledge and Process Management, 18(3): 121-132. 
 
Le Ber, M. & O. Branzei. 2011. Value Frame Fusion in Cross Sector Interactions. Journal of 
Business Ethics, 94: 163-195. 
 
Edelenbos, J. & E. Klijn. 2007. Trust in Complex Decision-Making Networks: A Theoretical and 
Empirical Exploration. Administration & Society, 39(1): 25-50. 
 
Lau, Kasper & M. Rond. 2006. The 'not invented here' myth. Nature Reviews Drug Discovery, 5: 
451-452. 
 
Maccoby, M., C. Norman, J. Norman & R. Margolies. 2013. Transforming Health Care 
Leadership: A Systems Guide to Improve Patient Care, Decrease Costs, and Improve Population 
Health. San Francisco, CA: Jossey-Bass. 
 
McNeill, D. 2013. A Framework for Applying Analytics in Healthcare. Upper Saddle River, NJ: 
Pearson Education. 
 
Michailova, S. & K. Husted. 2003. Knowledge-Sharing Hostility in Russian Firms. California 
Management Review, 45(3): 59-77. 
 
Mizruchi, M. S. & L. C. Fein. 1999. The social construction of organizational knowledge: A 
study of the uses of coercive, mimetic, and normative isomorphism. Administrative Science 
Quarterly, 44(4): 653-683. 
 
Miles, M. B. & M. A. Huberman. 1994. Qualitative data analysis: An expanded sourcebook. 
Thousand Oaks, CA: Sage. 
 
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
21 
Ministry of Interior and Social affairs. 2009. Status for the introduction of the structural reform – 
2009. Copenhagen, DK: Ministry of Interior and Social affairs. 
 
Moore, M. & J. Hartley. 2008. Innovations in Governance. Public Management Review 10(1): 3-
20. 
 
Nissen, H. A., M. R. Evald, & A. H. Clarke. 2014. Knowledge sharing in heterogeneous teams 
through collaboration and cooperation: Exemplified through Public-Private-Innovation 
partnerships. Industrial Marketing Management, 43(3): 473–482. 
 
Petticrew, M. & H. Roberts. 2006. Systematic Reviews in the Social Sciences. A Practical guide. 
Malden, MA: Blackwell publishing. 
 
Pol, E. & S. Ville. 2009. Social innovation: Buzz word or enduring term? The Journal of Socio-
Economics, 38(6): 878-885. 
 
Ragatz, G. L., R. B. Handfield & T. V. Scannell. 1997. Success Factors for Integrating Suppliers 
into New Product Development. Journal of Product Innovation Management, 14: 190–202. 
 
Rittel, H. W. & M. Webber. 1973. Dilemmas in a General Theory of Planning. Policy Sciences, 
4(6): 155-169. 
 
Rhodes, R. A. W. 1997. Understanding Governance. Buckingham, UK: Open University Press. 
 
Roy, R. N. & K. K. Guin. 1999. A proposed model of JIT purchasing in an integrated steel plant. 
International Journal of Production Economics, 59(1/3): 179–187. 
 
Roberts, N. C. & P. J. King. 1996. Transforming Public Policy: Dynamics of Policy 
Entrepreneurship and Innovation. San Francisco, CA: Jossey-Bass. 
 
Siggelkow, N. 2007. Persuasion with case studies. Academy of Management Journal, 50(1): 20-
24. 
 
Scott, R. W. 2003. Organizations: rational, natural and open systems. Englewood Cliffs, NJ: 
Prentice Hall. 
 
Schumpeter, J.A. 1939. Business cycles. New York, NY: McGraw-Hill.  
 
Schumpeter, J. 1934. The Theory of Economic Development. Cambridge, MA: Harvard 
University Press. 
 
Smith, D. 2010. Exploring innovation. London, UK: McGraw-Hill Higher Education. 
 
Shycon, H. N. 1978. All around the Model: Perspectives on MS Applications. Interfaces, 9(1): 
51-54. 
 
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
22 
Spicer, A. 2006. Beyond the Convergence–Divergence Debate: The Role of Spatial Scales in 
Transforming Organizational Logic. Organization Studies, 27(10): 1467–1483. 
 
Szulanski, G. 1996. Exploring internal stickiness: impediments to the transfer of best practice 
within the firm. Strategic Management Journal, 17: 27-43. 
 
Sørensen, E. & J. Torfing. 2011. Enhancing collaborative innovation in the public sector. 
Administration and Society, 43(8): 842-68. 
 
Sørensen, E. & J. Torfing. 2012. Introduction: Collaborative innovation in the public sector. 
Innovation Journal, 17(1): 1-14. 
 
Takahashi, N. & N. Inamizu. 2012. Mysteries of NIH Syndrome. Annals of Business 
Administrative Science, 11: 1-10. 
 
Tranfield, D., D. Denyer & P. Smart. 2003. Towards a Methodology for Developing Evidence-
Informed Management Knowledge by Means of Systematic Review. British Journal of 
Management, 14: 207-222. 
 
Tuschman, M. & P. Anderson. 1986. Technological Discontinuities and Organizational 
Environments. Administrative Science Quarterly, 31(3): 439-465. 
 
Twiss, B. 1992. Managing Technological Innovation. London, UK: Pearson Higher Education.  
 
Van de Ven, A. H., H. L. Angle & M. S. Poole. 1989. Research on the management of 
innovation.  The Minnesota studies. New York, NY: Harper & Row.  
 
Vargo, S. L. & R. F. Lusch. 2004. Evolving to a new dominant logic for marketing. Journal of 
Marketing, 68(1): 1-17. 
 
Vargo, S. L. & R. F. Lusch. 2008. Service-dominant logic: continuing the evolution. Journal of 
the Academy of marketing Science, 36(1): 1-10. 
 
Voronow, M. & R. Vince. 2012. Integrating emotions into the analysis of institutional work. 
Academy of Management Review, 37(1): 58-81. 
 
Voss, H. 2009. Private public collaboration about development and diffusion of new 
technologies in the healthcare sector. Copenhagen, DK: Danish Health Institute. 
 
Weihe, G., S. Højlund, T. B.  Holljen, E., O.H. Petersen, K. Vrangbæk, K., & 
J. Ladenburg. 2011. Strategic use of public–private cooperation in the Nordic region. TemaNord 
2011, 510. Copenhagen, DK: Nordic Council of Ministers. 
 
Yin, R. K. 2003. Case study research: Design and methods. Thousand Oaks, CA: Sage. 
The Innovation Journal: The Public Sector Innovation Journal, Volume 20(3), 2015, article 4.  
 ___________________________________________________________________________________________________________________________________________________________________________________________ 
 
23 
Appendix 1: NIH literature 
 
Overview of NIH literature, by journals, authors and research areas 
 
Journals Authors Research areas 
Management Science Hauser (1998) New product development 
(R&D) R&D Management Cheng & Wang (2008) 
R&D Management, Katz & Allen (1982) 
Nature Reviews Drug Discovery Lau & Rond (2006) 
Journal of Product Innovation 
Management 
Ragatz et al. (1997) 
Administrative Science 
Quarterly 
Cohen & Levinthal (1990) 
Journal of Technology Transfer Greiner & Franza (2003) 
Journal of Product Innovation 
Management, 
Griffin & Hauser (1996) 
Journal of Technology Transfer Kathoefer & Leker (2010) 
Administrative Science 
Quarterly 
Tuschman & Anderson (1986) 
 
Technovation Burcharth et al. (2014) Open innovation 
International Journal of 
Technology Management 
Herzog & Leker (2010) 
R&D Management Chesbrough & Growther (2006) 
R&D Management Gassmann (2006) 
 
International Journal of 
Technology Management 
Bessant (2008) Management (e.g. knowledge 
management, innovation 
management, group relations) Journal of Workplace Learning Dealtry (2008) 
R&D Management Lichtenthaler & Ernst (2006) 
Organization Science Lichtenthaler et al. (2010) 
Knowledge and Process 
Management 
Lilleoere & Hansen (2011) 
California Management Review Michailova & Husted (2003) 
International Journal of 
Production Economics 
Roy & Guin (1999) 
Interfaces Shycon, 1978 
Social Influence Adarves‐Yorno et al. (2008) 
Annals of Business 
Administrative Science 
Takahashi & Inamizu (2012) 
Annual Review of Psychology Bohner & Dickel (2011) 
Academy of Management 
Perspectives 
Antons & Pillar (2015) 
Strategic Management Journal Szulanski (1996) 
Advances in Health Care 
Management 
Chilingerian et al. (2005) 
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Appendix 2: Dominatant concepts in NIH literature 
An EBSCO Host database (Academic Search Premier and Business Source Complete) was used 
to identify NIH articles. As there is no clear definition of NIH, the first search was followed by a 
snowballing approach. Specifically, attention was paid to the terms and descriptions of the NIH 
phenomenon used in the articles found in the first search and additional author references used in 
relation to these were identified. 
Overview of the search approach used in EBSCO Host 
 Search words and total number of 
articles 
Number of articles selected  
First search* Search words: Not invented here 
Number of articles: 43 
18 
Second search Additional articles found through 
identification of new references of the 
articles selected for review 
12 
Total amount 
of articles 
Selection of 30 articles, which hereafter 
is  analyzed 
30 
*The keywords, abstracts and introductions were read and any relevant articles were selected for 
further review. 
 
Results from Leximancer 
All articles have been registered in the textual software program Leximancer. Subsequently, the 
program automatically conducted a contents description by identifying the most frequently 
appearing concepts. Concepts are collections of words that generally travel and occur together 
throughout the literature. Together with the most frequently occurring concepts, words that 
frequently co-occur with each concept are also identified in the program (Leximancer, 2011). 
The results produced by the program demonstrate that concepts related to knowledge and 
innovation is the most dominating ones throughout the NIH articles. 
The circles in the following figure reveal the most dominating concepts identified in the 
literature on NIH. The black text inside the circles represents frequently appearing words related 
to each concept. 
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Concepts ranked by their weight in the NIH literature  
 
Concept  Relative count 
Knowledge  100% 
Innovation  64% 
Project  20% 
Organization  19% 
Attitude  19% 
Licensing  19% 
Industries  01% 
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Appendix 3: Data overview 
 
Overview of the coding results for the four cases in which PPI firms experienced NIH as a 
constraint to commercialization of welfare innovations developed in PPI projects 
 
PPI projects Category/code Quote examples (PPI firms) 
Case 1 
Development of a tele-medicine 
solution aiming to provide 
treatment and control of a 
hospital’s chronic obstructive 
pulmonary disease (COPD) 
patients in their homes after 
discharge from the hospital. The 
public project partner was a 
hospital. 
Category: Diversification – 
commercialize broadly  
 
Category: Experience of 
NIH as a commercialization 
constraint in DK 
- We only engage in a project when we 
see real possibilities. 
 
- They want to provide treatment based on 
their own invention, and that’s how it is.  
Case 2 
Development of a self-propelled 
person lifter for heavily overweight 
patients in hospitals. The public 
project partner was a hospital. 
Category: Diversification - 
commercialize broadly  
 
 
Category: Experience of 
NIH as a commercialization 
constraint in DK 
- With these care products we are unique 
on the market for products that offer 
flexibility and such. 
 
- There are a lot of small ‘kingdoms’. 
There are a lot of conflicts of interest in 
this.  
 
Case 3 
Development of a series of product 
concepts for standard hospital- and 
nursing beds used by bed-ridden 
patients/residents at municipal 
nursing homes. The public project 
partner was a municipality.   
Category:  Diversification - 
commercialize broadly  
 
 
 
Category: Experience of 
NIH as a commercialization 
constraint in DK 
- It is obvious that there is something 
called ’time to market’, and we know that 
if we are not fast enough, then someone 
else will be faster than us. 
 
- I think that you are afraid that if you just 
adopt the neighbors’ things, then you do 
not get the recognition for developing 
something new yourself. Then it is just 
something which you have taken from 
another hospital.    
Case 4 
Development of a tele-medicine 
solution for virtual home visits at 
the homes of patients with chronic 
obstructive pulmonary disease 
(COPD) after their discharge from 
hospital. The public project 
partners included a hospital and a 
municipality. 
Category: Diversification - 
commercialize broadly  
 
 
 
Category: Experience of 
NIH as a commercialization 
constraint in DK 
- There are markets where we sell a 
product, where we in Denmark have not 
started to introduce it yet, even though the 
product has been developed in a project in 
Denmark. 
 
- Then there is a lot of competition among 
the regions. And when it is something that 
we have in the North Denmark Region, 
then you do not want it in the Central 
Denmark Region or in the Region of 
Southern Denmark. 
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The table provides an overview of the interviews conducted with the private firms in the 
four cases. 
 
Cases Firm respondents 
Case 1   Managing director 
Case 2   Key account manager, Medline & Careline Department 
Case 3   Regional manager 
Case 4   Managing director 
 
 
Overview of the interviews conducted with public stakeholders in relation to case 1 
 
Public organization Public respondents 
Hospital in the Central Denmark Region  Chief doctor and head of department 
Hospital in the Region of Southern Denmark  Head of hospital section for Operation and IT  
 Doctor and managing director of the hospital board 
 
 
 
 
